XML 21 R8.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Restricted stock units
Common stock
Common stock
Restricted stock units
Additional capital in excess of par value
Additional capital in excess of par value
Restricted stock units
Retained earnings
AOCI
 [1]
Beginning balance (in shares) at Dec. 31, 2019     235,214,000          
Balances at beginning of period at Dec. 31, 2019 $ 7,102.1   $ 47.0   $ 654.6   $ 6,443.5 $ (43.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 343.1           343.1  
Other comprehensive income (loss), net of tax (6.1)             (6.1)
Dividends declared (214.7)           (214.7)  
Shares issued upon option exercises (in shares)     1,068,000          
Shares issued upon option exercises 41.3   $ 0.2   41.1      
Net shares issued upon vesting of restricted stock units (in shares)       37,000        
Net shares issued upon vesting of restricted stock units   $ (3.0)       $ (3.0)    
Stock-based compensation expense 58.3       58.3      
Restricted stock units issued as dividend equivalents 0.0       0.1   (0.1)  
Common shares repurchased (in shares)     (8,334,000)          
Common shares repurchased (887.0)   $ (1.6)   (96.5)   (788.9)  
Ending balance (in shares) at Mar. 31, 2020     227,985,000          
Balances at end of period at Mar. 31, 2020 6,434.0   $ 45.6   654.6   5,782.9 (49.1)
Beginning balances attributable to redeemable non-controlling interests at Dec. 31, 2019 1,121.0              
Increase (Decrease) in Temporary Equity [Roll Forward]                
Net income (loss) attributable to redeemable non-controlling interests (176.5)              
Other comprehensive income (loss), net of tax, attributable to redeemable non-controlling interests 17.2              
Net subscriptions into consolidated T. Rowe Price investment products 63.8              
Net deconsolidations of T. Rowe Price investment products (20.1)              
Ending balances attributable to redeemable non-controlling interests at Mar. 31, 2020 971.0              
Beginning balance (in shares) at Dec. 31, 2020     227,965,000          
Balances at beginning of period at Dec. 31, 2020 7,707.0   $ 45.6   654.6   7,029.8 (23.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 749.4           749.4  
Other comprehensive income (loss), net of tax (7.5)             (7.5)
Dividends declared $ (252.3)           (252.3)  
Shares issued upon option exercises (in shares) 748,203   572,000          
Shares issued upon option exercises $ 25.4   $ 0.1   25.3      
Net shares issued upon vesting of restricted stock units (in shares)       41,000        
Net shares issued upon vesting of restricted stock units   $ (3.7)       $ (3.7)    
Stock-based compensation expense 57.5       57.5      
Restricted stock units issued as dividend equivalents         0.1   (0.1)  
Common shares repurchased (in shares)     (1,630,000)          
Common shares repurchased (267.6)   $ (0.3)   (79.2)   (188.1)  
Ending balance (in shares) at Mar. 31, 2021     226,948,000          
Balances at end of period at Mar. 31, 2021 8,008.2   $ 45.4   $ 654.6   $ 7,338.7 $ (30.5)
Beginning balances attributable to redeemable non-controlling interests at Dec. 31, 2020 1,561.7              
Increase (Decrease) in Temporary Equity [Roll Forward]                
Net income (loss) attributable to redeemable non-controlling interests 15.4              
Other comprehensive income (loss), net of tax, attributable to redeemable non-controlling interests 11.8              
Net subscriptions into consolidated T. Rowe Price investment products 187.5              
Net deconsolidations of T. Rowe Price investment products (739.9)              
Ending balances attributable to redeemable non-controlling interests at Mar. 31, 2021 $ 1,012.9              
[1] Accumulated other comprehensive income.